Off-Patent Drugs APPG

First Registered: 29/09/2015 • Last updated on: 05/11/2019

Note: This APPG was last registered on 5th Nov 2019. The APPG was not registered in the latest release of 6th Oct 2021 and may be defunct.

To raise the issue of accessibility of off-patent drugs within Parliament; to raise issues of relevance with government and policy makers; and to influence policy to improve access.

Note: All-Party Parliamentary Groups (APPGs) are informal, cross-party groups formed by MPs and Members of the House of Lords who share a common interest in a particular policy area, region or country. APPGs have no official status within Parliament.

Former Members - Contact Details - Benefits in Kind - Financial Benefits

This content was generated for your convenience by Parallel Parliament and does not form part of the official record.
Recent Documents related to Off-Patent Drugs

1. National Society for Phenylketonuria - written evidence
04/03/2019 - Inquiry: Availability of Orkambi on the NHS - Health and Social Care Committee
- View source

Found: approach. Sir Andrew Dillon said “in evaluating HST drugs, NICE takes into account a greater range of criteria

2. Breast Cancer Now - written evidence
05/09/2018 - Inquiry: Funding priorities in the 2018-19 Budget: Health - Northern Ireland Affairs Committee
- View source

Found: medicines. How can access to cancer treatment and drugs be improved in Northern Ireland? Speeding up the

3. Bill 14 2015-16, as introduced
05/11/2015 - Bill Documents

Found: Bill 14 56/1Off-patent Drugs BillEXPLANATORY NOTESExplanatory notes to the Bill, prepared by Nick Thomas-Symonds

4. Bill 14-EN 2015-16
05/11/2015 - Bill Documents

Found: Bill14ŒEN56/1 OFF-PATENT DRUGS BILL EXPLANATORY NOTES What these notes do TheseExplanatory Notesrelate

5. STOPAIDS - written evidence
04/03/2019 - Inquiry: Availability of Orkambi on the NHS - Health and Social Care Committee
- View source

Found: must now use their legal right to suspend Vertex’s patent and issue a Crown Use license to get access to

Latest Documents
Recent Speeches related to Off-Patent Drugs

1. Orkambi
04/02/2019 - Commons Chamber

1: year that access to Orkambi or other such similar drugs is delayed takes 10 years off the life of his daughter - Speech Link
2: alternative that allows NICE to spend taxpayers’ money on drugs for other conditions while still allowing cystic - Speech Link
3: high, and this is entirely due to the powerful patent laws that allow pharmaceutical companies to monopolise - Speech Link

2. Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020
27/11/2020 - Lords Chamber

1: supporting the development of new drugs and ensuring that those drugs become available more cheaply, through - Speech Link
2: protection certificates have been a feature of EU patent protection for medicines and plant products for - Speech Link
3: money and in the time that it takes to develop drugs and some agrochemicals, it makes sense to provide - Speech Link

3. Intellectual Property Rights: Affordable Drugs
30/11/2020 - Lords Chamber

1: Property Rights to guarantee access to affordable drugs in (1) the United Kingdom, and (2) developing countries - Speech Link
2: sums of public money invested in developing new drugs and treatments, notwithstanding the need to generate - Speech Link
3: countries have access to affordable and necessary drugs, and, even more importantly, advice on how they - Speech Link

4. Patents (Amendment) (EU Exit) Regulations 2018
06/02/2019 - Lords Chamber

1: economy; the companies which research and develop new drugs are some of our most important and valuable, and - Speech Link
2: Minister’s—this flaw reduces the period of exclusivity for drugs authorised in the UK, because the start of the period - Speech Link
3: with the question of participation in the unified patent court, as set out in the White Paper last autumn - Speech Link

5. Breast Cancer Drugs
26/01/2017 - Commons Chamber

1: to both innovative new breast cancer drugs and off-patent drugs used for breast cancer, such as bisphosphonates - Speech Link
2: to both innovative new breast cancer drugs and off-patent drugs used for breast cancer, such as bisphosphonates - Speech Link
3: issues with how NICE assesses new drugs, particularly cutting-edge drugs such as Kadcyla. He will know, - Speech Link

Latest Speeches
Recent Questions related to Off-Patent Drugs
1. Unified Patent Court
asked by: Lord Stevenson of Balmacara
24/07/2020
... and (2) of any future wind down costs consequent on their decision to withdraw their ratification of the Agreement on a Unified Patent Court and the Protocol on Privileges and Immunities of the Unified Patent Court. [T]

2. Unified Patent Court
asked by: Lord Anderson of Ipswich
24/03/2020
...To ask Her Majesty's Government what assessment they have made of the impact on research-led SMEs of the reported decision to withhold the UK's participation in the Unified Patent Court and the associated Unitary Patent.

3. Unified Patent Court
asked by: Bill Esterson
11/12/2017
... what plans he has to maintain UK membership of the Unified Patent Court after the UK leaves the EU.

4. European Patent Office
asked by: Barry Gardiner
10/11/2017
... whether the UK will remain a member of the European Patent Office after the UK leaves the EU.

5. Unified Patent Court
asked by: Lord Cromwell
19/04/2017
... in accordance with the announcement by Baroness Neville-Rolfe at the October 2015 EU Competitiveness Council.

Latest Questions
Former APPG Members
Nick Thomas-Symonds Portrait
Nick Thomas-Symonds
Chair & Registered Contact
Labour - Torfaen
Joined: 29th September 2015
Departed: 5th November 2019
No other APPG Memberships
Robert Neill Portrait
Robert Neill
Vice Chair
Conservative - Bromley and Chislehurst
Joined: 28th September 2017
Departed: 5th November 2019
Nia Griffith Portrait
Nia Griffith
Vice Chair
Labour - Llanelli
Joined: 29th September 2015
Departed: 5th November 2019
1 APPG Membership
Modern Languages
Jo Stevens Portrait
Jo Stevens
Vice Chair
Labour - Cardiff Central
Joined: 29th September 2015
Departed: 5th November 2019

No benefits in kind are on record for the Off-Patent Drugs APPG

No direct financial benefits are on record for the Off-Patent Drugs APPG